Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: protocol for a systematic review and meta-analysis
Top Cited Papers
Open Access
- 8 April 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Systematic Reviews
- Vol. 9 (1), 1-6
- https://doi.org/10.1186/s13643-020-01343-4
Abstract
A new type of coronavirus, novel coronavirus (COVID-19), is causing an increasing number of cases of pneumonia and was declared a Public Health Emergency of International Concern by the World Health Organization on 30 January 2020. The virus first appeared in Wuhan, China, in late December 2019, and traditional Chinese herbal medicine is being used for its treatment. This systematic review and meta-analysis will assess studies of the effects of traditional Chinese herbal medicine in COVID-19 pneumonia. We will search electronic databases including PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Science and Technology Periodical Database (VIP), and Wanfang database using keywords related to COVID-19 and traditional Chinese herbal medicine. Reference lists of relevant trials and reviews will be searched. We will manually search gray literature, such as conference proceedings and academic degree dissertations, and trial registries. Two independent reviewers will screen studies (XL and DZ), extract data (YL and LG), and evaluate risk of bias (YL and DZ). Data analysis will be conducted using the Review Manager software (version 5.3.5) and R software (version 3.6.1). Statistical heterogeneity will be assessed using a standard chi-square test with a significance level of P < 0.10. Biases associated with study size (e.g., publication bias) will be investigated using funnel plots, Egger’s test and Begg’s test, and Trim and Fill analysis. This study will provide a high-quality synthesis of the effects of traditional Chinese herbal medicine for COVID-19. The use of traditional Chinese herbal medicine for treatment or prevention of these novel viral infections affecting the pneumonia will be investigated. PROSPERO registration number: CRD42020168004Other Versions
This publication has 31 references indexed in Scilit:
- Chinese herbs combined with Western medicine for severe acute respiratory syndrome (SARS)Emergencias, 2012
- Effect of Immunoglobulin Therapy on the Rate of Infections in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation and or treated with immunomodulatory agentsMediterranean Journal of Hematology and Infectious Diseases, 2010
- Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analysesJournal of Clinical Epidemiology, 2008
- Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysisJournal of Clinical Epidemiology, 2008
- The Efficacy of Chinese Medicine for SARS: A Review of Chinese Publications After the CrisisThe American Journal of Chinese Medicine, 2007
- [Effect of glucocorticoid with traditional Chinese medicine in severe acute aespiratory syndrome (SARS)].2005
- TCM treatment of infectious atypical pneumonia--a report of 16 cases.2004
- Grading quality of evidence and strength of recommendationsBMJ, 2004